1-20 of 75
Steven Coutre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS

Navika D. Shukla, Joseph Schroers-Martin, Karan R. Kathuria, Brian Sworder, Stefan K. Alig, Matthew J Frank, David B. Miklos, Steven Coutre, Maximilian Diehn, Michael S. Khodadoust, Mark Roschewski, David M. Kurtz, Ash A. Alizadeh
Journal: Blood
Blood (2022) 140 (Supplement 1): 6403–6404.
https://doi.org/10.1182/blood-2022-165656
Published: 2022
Journal Articles

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902)

Deborah M. Stephens, Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch, Alexey V. Danilov, David Ng, Anthony R. Mato, Danielle M. Brander, Megan Othus, Steven Coutre, Susan M. O'Brien, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 2630.
https://doi.org/10.1182/blood-2021-144780
Published: 2021
Journal Articles

Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study

Tanya Siddiqi, Pamela Clay, Kate Murray, Navshina Shekh, Alexandra Muir, Steven T. Rosen, Steven Coutre
Journal: Blood
Blood (2021) 138 (Supplement 1): 3754.
https://doi.org/10.1182/blood-2021-154203
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021
Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Priyanka A Pophali, Xin Victoria Wang, Fengmin Zhao, Neil E. Kay, Curtis A. Hanson, Mary L. Thomas, Susan M. O'Brien, Jacqueline Barrientos, Elisabeth M. Paietta, Jose F. Leis, Cong Christine Zhang, Steven Coutre, Paul M. Barr, Amanda Cashen, Anthony R. Mato, Avina Singh, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Tait Shanafelt, Lynne I. Wagner
Journal: Blood
Blood (2021) 138 (Supplement 1): 1562.
https://doi.org/10.1182/blood-2021-150462
Published: 2021
Journal Articles

Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML

Gavin Hui, MD, Abdullah Ladha, MD, Edna Cheung, PharmD, Caroline Berube, MD, Steven Coutre, MD, Jason Gotlib, MD MS, Michaela Liedtke, MD, Tian Y Zhang, MD PhD, Lori S. Muffly, MD MS, Gabriel N. Mannis, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-142691
Published: 2020
Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD MS, Diane F Jelinek, PhD, Esteban Braggio, PhD, Jose F. Leis, MD PhD, Cong Christina Zhang, Steven Coutre, MD, Paul M. Barr, MD, Amanda F Cashen, MD, Anthony R. Mato, MD MSCE, Avina Singh, MD, Michael P. Mullane, MD, Richard F. Little, MD MPH, Harry P. Erba, MD PhD, Richard M. Stone, MD, Mark Litzow, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 33.
https://doi.org/10.1182/blood-2019-126824
Published: 2019
Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Jeff P. Sharman, MD, Versha Banerji, MD, Laura Maria Fogliatto, MD PhD, Yair Herishanu, MD, Talha Munir, MD, Renata Walewska, George Follows, Karin Karlsson, MD, Paolo Ghia, MD PhD, Gillian Corbett, Patricia Walker, MBBS, Miklos Egyed, Wojciech Jurczak, MD PhD, Gilles Salles, MD PhD, Ann Janssens, Florence Cymbalista, MD PhD, William G. Wierda, MD PhD, Steven Coutre, MD, John M. Pagel, MD PhD DSc, Alan Skarbnik, MD, Manali Kamdar, MD, Jennifer Woyach, MD, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Priti Patel, MD, Min Hui Wang, PhD, Sofia Wong, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 31.
https://doi.org/10.1182/blood-2019-128404
Published: 2019
Journal Articles

Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia

Bing-E Xu, PhD, Kristen M Rosenthal, PhD, Krista Marcello, BA, Farrukh T. Awan, MD, Steven Coutre, MD, Nicole Lamanna, MD, Jeff P. Sharman, MD, Timothy A Quill, PhD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4724.
https://doi.org/10.1182/blood-2019-129266
Published: 2019
Journal Articles

A one-two punch with VO KOs CLL

Steven Coutre
Journal: Blood
Blood (2019) 133 (26): 2737–2738.
https://doi.org/10.1182/blood-2019-04-901116
Published: 2019
Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Clinical Trials & Observations
John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown
Journal: Blood
Blood (2019) 133 (19): 2031–2042.
https://doi.org/10.1182/blood-2018-08-870238
Published: 2019
Includes: Supplemental data
Journal Articles

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, PhD, Nyla A. Heerema, PhD, Weiqiang Zhao, MD PhD, Allison M Booth, Wei Ding, MD PhD, Nancy L. Bartlett, MD, Danielle M. Brander, MD, Paul Barr, MD, Kerry A. Rogers, MD, Sameer A. Parikh, MD, Steven Coutre, MD, Arti Hurria, MD, Gerard Lozanski, MD, Sreenivasa Nattam, MD, Richard A. Larson, MD, Harry P. Erba, MDPhD, Mark R. Litzow, MD, Carolyn Owen, Jim Atkins, Jeremy S. Abramson, MD MMSc, Richard F. Little, MD MPH, Scott E. Smith, MD PhD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 6.
https://doi.org/10.1182/blood-2018-99-116653
Published: 2018
Journal Articles

Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD PhD, Jan A. Burger, MD PhD, Kristie A. Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Ying Luan, PhD, Emily A. Liu, PhD, James P. Dean, MD PhD, Susan M. O'Brien, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2018-99-110847
Published: 2018
Journal Articles

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Clinical Trials & Observations
Abby Statler, Megan Othus, Harry P. Erba, Thomas R. Chauncey, Jerald P. Radich, Steven Coutre, Anjali Advani, Sucha Nand, Farhad Ravandi, Sudipto Mukherjee, Mikkael A. Sekeres
Journal: Blood
Blood (2018) 131 (25): 2782–2788.
https://doi.org/10.1182/blood-2018-01-826693
Published: 2018
Includes: Supplemental data
Journal Articles

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Clinical Trials & Observations Brief Report
Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutre, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan
Journal: Blood
Blood (2018) 131 (21): 2331–2334.
https://doi.org/10.1182/blood-2017-09-803072
Published: 2018
Includes: Supplemental data
Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Clinical Trials & Observations
Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd
Journal: Blood
Blood (2018) 131 (17): 1910–1919.
https://doi.org/10.1182/blood-2017-10-810044
Published: 2018
Includes: Supplemental data
Journal Articles

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Clinical Trials & Observations
Steven Coutre, Michael Choi, Richard R. Furman, Herbert Eradat, Leonard Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids
Journal: Blood
Blood (2018) 131 (15): 1704–1711.
https://doi.org/10.1182/blood-2017-06-788133
Published: 2018
Includes: Supplemental data
Journal Articles

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Clinical Trials & Observations
Ronan T. Swords, Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, Jesus G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona
Journal: Blood
Blood (2018) 131 (13): 1415–1424.
https://doi.org/10.1182/blood-2017-09-805895
Published: 2018
Includes: Supplemental data
Journal Articles

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Anthony R. Mato, MD, William G Wierda, MD PhD, Matthew S. Davids, MD, Bruce D. Cheson, MD, Steven Coutre, MD, Michael Choi, MD, Richard R. Furman, Leonard Heffner, MD, Paul M. Barr, MD, Herbert Eradat, Lang Zhou, Maria Verdugo, MD, Jalaja Potluri, Jeffrey Jones, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 834.
https://doi.org/10.1182/blood.V130.Suppl_1.834.834
Published: 2017
Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2765.
https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765
Published: 2017